Sequencing Market Entry to Build Durable Biotech Moats

BillionToOne shows that the most durable competitive advantages in biotech do not come from moonshot funding, but from sequencing market entry to solve a needle in the haystack problem. By choosing prenatal diagnostics as a lower cost entry point, the founders avoided massive, pre-revenue capital raises and built a self-sustaining system that funds its own research. This strategy proves that systemic thinking, specifically mapping the technical commonality between fetal DNA and tumor DNA, allows a company to compound its expertise across different medical fields. For investors and operators, the lesson is clear: build a moat by solving a difficult technical problem in a high-frequency, low-barrier market first, then use that infrastructure to attack higher-stakes goals like early-stage cancer detection.

The Hidden Cost of Solving Everything at Once

Most biotech startups fail because they try to solve a high-stakes problem, like early-stage cancer screening, without a revenue engine to sustain their research. BillionToOne founders David Tsao and Oguzhan Atay inverted this model. They identified that the technical challenge of detecting rare DNA fragments in blood was identical for both fetal diagnostics and oncology.

By starting with prenatal testing, they solved the immediate problem of commercialization and scale. This created a feedback loop where revenue from the prenatal business funded the development of oncology tools. Had they attempted the oncology goal first, they would have needed over a billion dollars in capital before proving the technology worked. Instead, they built a 20% market share in prenatal testing, which provided the data and capital to tackle late-stage cancer, and eventually, early-stage detection.

"If you wanted to solve early detection from the very beginning without having this step by step approach you would have to raise more than a billion dollars you know without generating a single dollar of revenue."

-- Oguzhan Atay

Why the Obvious Fix Makes Things Worse

In molecular diagnostics, the standard way to find rare DNA is to amplify the sample using PCR. However, this process introduces noise, which are errors that obscure the signal. Most labs accept this noise as a cost of doing business. BillionToOne decided to treat the amplification process itself as a variable to be corrected. By adding synthetic DNA to the sample before amplification, they created a reference point to measure and subtract the distortion.

This shifts the challenge from a purely biological one to a mathematical one. The result is a significant reduction in false results, which is critical for medical outcomes. This is a classic example of systems thinking: by acknowledging that the measurement tool, PCR, is part of the system and inherently flawed, they built a noise-cancellation layer that competitors, who were busy trying to perfect the chemistry alone, missed.

"This converts a difficult biology problem to almost a simple mathematical problem."

-- Oguzhan Atay

The 18-Month Payoff: Where Immediate Pain Creates Moats

The founders decided to build an interdisciplinary team, hiring people who could bridge fields rather than just specialists. This is a structural choice that favors long-term speed over short-term ease. By having scientists own the end-to-end development of a product, they eliminated the bureaucratic friction that slows down most large organizations.

This creates a startup within a company dynamic. Because these teams report directly to the founders, they are unblocked quickly. While this creates intense pressure, which the founders call a privilege, it results in an iterative cycle that operates much faster than competitors. The discomfort of this high-pressure, high-ownership environment is what prevents competitors from catching up. It is a culture designed for durability, not comfort.

Key Action Items

• Audit your needle in the haystack problem: Identify the specific noise in your current process that you are treating as an unavoidable cost. Can you introduce a synthetic marker to measure that noise and subtract it mathematically? (Immediate)
• Sequence your market entry: If your long-term goal requires massive capital, identify a smaller, high-frequency step one market that uses the same core technology. This creates the cash flow necessary to fund the big goal later. (Next 3-6 months)
• Flatten the R&D structure: Remove layers of management between the founders and the scientists doing the actual work. If a scientist cannot iterate on a product end-to-end, you are losing speed to bureaucracy. (Next quarter)
• Prioritize interdisciplinary hiring: Stop hiring for specific silos. Look for individuals who can bridge the gap between data science and the physical chemistry of your product. (Ongoing)
• Build the happy path automation: Use computer vision and robotics to handle high-volume, repetitive tasks like sample accessioning so your human talent can focus on the edge cases that require expert judgment. (12-18 months)
• Leverage pressure as a privilege: When scaling, communicate clearly that the work is difficult. High-performing talent is often attracted to the challenge of solving impossible problems, not just the compensation. (Ongoing)